- Home
- GROV vs ATNM Comparison
GROV vs ATNM Comparison
Compare GROV & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROV
- ATNM
- Stock Information
- Founded
- GROV 2016
- ATNM 2000
- Country
- GROV United States
- ATNM United States
- Employees
- GROV N/A
- ATNM N/A
- Industry
- GROV Package Goods/Cosmetics
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- GROV Consumer Discretionary
- ATNM Health Care
- Exchange
- GROV Nasdaq
- ATNM Nasdaq
- Market Cap
- GROV 56.5M
- ATNM 56.5M
- IPO Year
- GROV N/A
- ATNM N/A
- Fundamental
- Price
- GROV $1.39
- ATNM $1.44
- Analyst Decision
- GROV Buy
- ATNM Strong Buy
- Analyst Count
- GROV 1
- ATNM 5
- Target Price
- GROV $2.00
- ATNM $10.20
- AVG Volume (30 Days)
- GROV 96.9K
- ATNM 256.8K
- Earning Date
- GROV 11-12-2024
- ATNM 11-14-2024
- Dividend Yield
- GROV N/A
- ATNM N/A
- EPS Growth
- GROV N/A
- ATNM N/A
- EPS
- GROV N/A
- ATNM N/A
- Revenue
- GROV $213,781,000.00
- ATNM $81,000.00
- Revenue This Year
- GROV N/A
- ATNM $186.10
- Revenue Next Year
- GROV $5.97
- ATNM $19,248.94
- P/E Ratio
- GROV N/A
- ATNM N/A
- Revenue Growth
- GROV N/A
- ATNM N/A
- 52 Week Low
- GROV $1.19
- ATNM $1.33
- 52 Week High
- GROV $2.44
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- GROV 53.54
- ATNM 36.55
- Support Level
- GROV $1.30
- ATNM $1.37
- Resistance Level
- GROV $1.41
- ATNM $1.97
- Average True Range (ATR)
- GROV 0.09
- ATNM 0.12
- MACD
- GROV 0.00
- ATNM -0.03
- Stochastic Oscillator
- GROV 44.64
- ATNM 12.40
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.